Amicus Therapeutics
FOLD · NASDAQ
Price unavailable right now.
No price history for this range.
EPS: actual vs estimate
Beat the estimate in 4 of the last 8 quarters, by 86.5% on average
Next report: , before the market opens
- Quarter
- Q3 FY26
- EPS estimate
- $0.13
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q4 FY25 | $0.0885 | $0.005 | −94.4% |
| Q3 FY25 | $0.0393 | $0.06 | +52.7% |
| Q2 FY25 | -$0.1201 | -$0.07 | +41.7% |
| Q1 FY25 | -$0.0555 | -$0.07 | −26.1% |
| Q4 FY24 | $0.0147 | $0.05 | +240.1% |
| Q3 FY24 | $0.00 | -$0.02 | +0.0% |
| Q2 FY24 | -$0.0566 | -$0.05 | +11.7% |
| Q1 FY24 | -$0.0669 | -$0.16 | −139.2% |
Earnings calls
- UBS Global Healthcare Conference 2025
- FOLD - Earnings call Q3 2025
- Morgan Stanley 23rd Annual Global Healthcare Conference
- FOLD - Earnings call Q2 2025
- Goldman Sachs 46th Annual Global Healthcare Conference 2025
- BofA Securities 2025 Healthcare Conference
- FOLD - Earnings call Q1 2025
- 2024 Earnings Call
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.